Dataset Information

Ready or not, here it comes: Direct-to-consumer pharmacogenomic testing and its implications for community pharmacists.

ABSTRACT: OBJECTIVE:To explore the implications of direct-to-consumer pharmacogenomic testing for community pharmacy practice. SUMMARY:In October 2018, the U.S. Food and Drug Administration provided approval for direct-to-consumer genetic testing company, 23andMe (Mountain View, CA), to return select pharmacogenomic test results to their customers. Given the community pharmacist's high accessibility to the public and in-depth knowledge of pharmacology, and the availability of direct-to-consumer genetic testing kits at pharmacies, it is likely that patients will present their pharmacogenomic test results to their pharmacists and expect them to incorporate those results into their care. It is important, therefore, that community pharmacists are aware of the clinical implications of these results, know where to turn for evidence-based clinical pharmacogenomics information, and be mindful of the need for confirmatory testing before changing therapy. CONCLUSION:Community pharmacists are at the frontlines of health care, and as such will be at the frontlines of direct-to-consumer pharmacogenomic testing. In the near future, it is likely that community pharmacists will need to counsel patients on the interpretation and appropriate use of direct-to-consumer pharmacogenomic test results.

SUBMITTER: Gammal RS

PROVIDER: S-EPMC7229642 | biostudies-literature | 2019 Sep - Oct

REPOSITORIES: biostudies-literature

ACCESS DATA

Publications

Ready or not, here it comes: Direct-to-consumer pharmacogenomic testing and its implications for community pharmacists.

Gammal Roseann S RS Mayes Jason J Caudle Kelly E KE

Journal of the American Pharmacists Association : JAPhA 20190718 5

<h4>Objective</h4>To explore the implications of direct-to-consumer pharmacogenomic testing for community pharmacy practice.<h4>Summary</h4>In October 2018, the U.S. Food and Drug Administration provided approval for direct-to-consumer genetic testing company, 23andMe (Mountain View, CA), to return select pharmacogenomic test results to their customers. Given the community pharmacist's high accessibility to the public and in-depth knowledge of pharmacology, and the availability of direct-to-cons ...[more]

PMID: 31327749

Similar Datasets

Project description:BACKGROUND:Rapid advances in scientific research have led to an increase in public awareness of genetic testing and pharmacogenetics. Direct-to-consumer (DTC) genetic testing companies, such as 23andMe, allow consumers to access their genetic information directly through an online service without the involvement of healthcare professionals. Here, we evaluate the clinical relevance of pharmacogenetic tests reported by 23andMe in their UK tests. METHODS:The research papers listed under each 23andMe report were evaluated, extracting information on effect size, sample size and ethnicity. A wider literature search was performed to provide a fuller assessment of the pharmacogenetic test and variants were matched to FDA recommendations. Additional evidence from CPIC guidelines, PharmGKB, and Dutch Pharmacogenetics Working Group was reviewed to determine current clinical practice. The value of the tests across ethnic groups was determined, including information on linkage disequilibrium between the tested SNP and causal pharmacogenetic variant, where relevant. RESULTS:23andMe offers 12 pharmacogenetic tests to their UK customers, some of which are in standard clinical practice, and others which are less widely applied. The clinical validity and clinical utility varies extensively between tests. The variants tested are likely to have different degrees of sensitivity due to different risk allele frequencies and linkage disequilibrium patterns across populations. The clinical relevance depends on the ethnicity of the individual and variability of pharmacogenetic markers. Further research is required to determine causal variants and provide more complete assessment of drug response and side effects. CONCLUSION:23andMe reports provide some useful pharmacogenetics information, mirroring clinical tests that are in standard use. Other tests are unspecific, providing limited guidance and may not be useful for patients without professional interpretation. Nevertheless, DTC companies like 23andMe act as a powerful intermediate step to integrate pharmacogenetic testing into clinical practice.

Dataset Information

Ready or not, here it comes: Direct-to-consumer pharmacogenomic testing and its implications for community pharmacists.

Publications

Ready or not, here it comes: Direct-to-consumer pharmacogenomic testing and its implications for community pharmacists.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets